Summary of Pulse Biosciences FY Conference Call Company Overview - **Company**: Pulse Biosciences (NasdaqCM:PLSE) - **Industry**: Medical Devices, specifically focusing on electrophysiology (EP) and atrial fibrillation (AF) treatment Key Points and Arguments Clinical Data and Product Efficacy - Pulse Biosciences presented data on the NS 360 catheter, achieving 100% efficacy in rhythm control at 6 months and 96% at 12 months, with 90% freedom from all atrial arrhythmias at 12 months [4][5][6] - The company attributes its success to the use of nanosecond pulsed field ablation (PFA), which allows for a more efficient energy delivery and a contiguous lesion creation, leading to deeper and higher quality lesions compared to traditional methods [6][7][10] - The total energy delivered by Pulse's system is lower than that of competitors, yet it achieves better outcomes due to the efficiency of energy penetration into tissue [10][11][12] Integration with Mapping Systems - The integration of mapping systems in the EFS study was noted as suboptimal, but improvements are expected in future studies with higher fidelity registration [13][19][20] - The company anticipates that better integration with mapping systems will enhance procedural efficiency and potentially improve outcomes, although achieving higher efficacy than 96% may be challenging [20][21] IDE Study and Enrollment - Pulse Biosciences has received IDE approval for a study involving 155 patients, targeting paroxysmal AF, with enrollment expected to begin in Q2 2026 [23][24] - The study is designed to be efficient, with the potential for multiple patients to be enrolled per site per day, which is expected to accelerate the enrollment process [25][30] Strategic Direction and Market Position - The company is focusing on the EP market, which is seen as highly attractive due to its growth potential [35][36] - Pulse Biosciences plans to pursue partnerships rather than building a complete organization independently, as this is viewed as a more efficient strategy to leverage their disruptive technology [37][38] - The company is positioned to combine its unique energy technology with mapping systems to capture significant market share in the coming years [38][39] Financial Outlook and Cash Management - As of the end of 2025, Pulse Biosciences had $80 million in cash, with additional funding options available through a $60 million ATM and a $200 million shelf registration [45] - The company expects an increase in cash burn throughout 2026, primarily due to the costs associated with the IDE studies [47][48] Conclusion - Pulse Biosciences is poised for significant advancements in the EP market with its innovative catheter technology and strong clinical data. The focus on strategic partnerships and efficient enrollment in clinical studies is expected to drive growth and enhance shareholder value moving forward [41][42][46]